Swedish Orphan Biovitrum AB (publ)
BIOVF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $26 | $22 | $19 | $16 |
| % Growth | 17.6% | 17.7% | 21% | – |
| Cost of Goods Sold | $6 | $5 | $5 | $3 |
| Gross Profit | $20 | $17 | $14 | $12 |
| % Margin | 77.8% | 77.4% | 74.6% | 77.6% |
| R&D Expenses | $4 | $3 | $2 | $2 |
| G&A Expenses | $8 | $10 | $8 | $6 |
| SG&A Expenses | $11 | $10 | $8 | $6 |
| Sales & Mktg Exp. | $4 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | $0 | -$0 | -$0 |
| Operating Expenses | $15 | $13 | $10 | $8 |
| Operating Income | $6 | $4 | $4 | $4 |
| % Margin | 21.6% | 18.4% | 20.3% | 24% |
| Other Income/Exp. Net | -$1 | -$1 | -$0 | -$0 |
| Pre-Tax Income | $4 | $3 | $3 | $3 |
| Tax Expense | $1 | $1 | $1 | $1 |
| Net Income | $4 | $2 | $3 | $3 |
| % Margin | 14.9% | 10.9% | 14% | 17.3% |
| EPS | 11.37 | 7.39 | 8.52 | 8.67 |
| % Growth | 53.9% | -13.3% | -1.7% | – |
| EPS Diluted | 11.24 | 7.39 | 8.44 | 8.62 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $1 | $0 | $0 |
| Depreciation & Amortization | $4 | $3 | $2 | $2 |
| EBITDA | $9 | $7 | $6 | $6 |
| % Margin | 35.7% | 32.7% | 32.2% | 36.8% |